文献速递肝病消化道肿瘤与早癌

脯氨酸生物合成通路促进肝肿瘤发生

Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
PubMed 文献 · J Hepatol · 2019-11-11

该研究比较Morris肝癌与DEN诱导肝癌模型的基因表达谱,发现脯氨酸合成酶PYCR1在肝癌中显著上调;敲低PYCR1抑制肝癌细胞增殖与体内肿瘤生长,过表达则增强增殖,且对非癌细胞无影响;PYCR1表达与肿瘤分级相关并独立预测临床结局。

要点

  • PYCR1在肝癌模型中显著上调,敲低可抑制肝癌细胞增殖和肿瘤生长。
  • PYCR1过表达增强肝癌细胞增殖,但对非癌细胞增殖无影响。
  • PYCR1表达与肿瘤分级相关,是临床结局的独立预测因素。

核心结论

  • 脯氨酸生物合成酶表达增强促进肝细胞癌细胞增殖。
  • 抑制PYCR1或ALDH18A1可能成为靶向肝癌的新治疗策略。

研究设计与样本

  • 比较Morris肝癌(MH3924a)与DEN诱导肝癌模型及正常和快速再生肝模型的基因表达谱。
  • 对 identified 基因靶点进行体外和体内功能获得与缺失研究。

主要发现

  • PYCR1被鉴定为肝癌模型中上调最显著的基因之一。
  • 敲低PYCR1显著降低多种肝癌细胞系体外增殖和体内肿瘤生长。
  • 过表达PYCR1增强肝癌细胞系增殖。
  • PYCR1表达在再生肝中未升高,且敲低或过表达对非癌细胞增殖无影响。
  • ALDH18A1等其他脯氨酸生物合成酶在肝癌模型中上调并调控肝癌细胞增殖。

关键数值与推荐

  • 临床数据显示PYCR1在肝癌中表达增加,与肿瘤分级相关,是临床结局的独立预测因素。

临床怎么用

  • 提示靶向脯氨酸生物合成通路关键酶PYCR1或ALDH18A1可能为肝癌治疗提供新方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIM: Under the regulation of various oncogenic pathways, cancer cells undergo adaptive metabolic programming to maintain specific metabolic states that support their uncontrolled proliferation. As it has been difficult to directly and effectively inhibit oncogenic signaling cascades with pharmaceutical compounds, focusing on the downstream metabolic pathways that enable indefinite growth may provide therapeutic opportunities. Thus, we sought to characterize metabolic changes in hepatocellular carcinoma (HCC) development and identify metabolic targets required for tumorigenesis. METHODS: We compared gene expression profiles of Morris Hepatoma (MH3924a) and DEN (diethylnitrosamine)-induced HCC models to those of liver tissues from normal and rapidly regenerating liver models, and performed gain- and loss-of-function studies of the identified gene targets for their roles in cancer cell proliferation in vitro and in vivo. RESULTS: The proline biosynthetic enzyme PYCR1 (pyrroline-5-carboxylate reductase 1) was identified as one of the most upregulated genes in the HCC models. Knockdown of PYCR1 potently reduced cell proliferation of multiple HCC cell lines in vitro and tumor growth in vivo. Conversely, overexpression of PYCR1 enhanced the proliferation of the HCC cell lines. Importantly, PYCR1 expression was not elevated in the regenerating liver, and KD or overexpression of PYCR1 had no effect on proliferation of non-cancerous cells. Besides PYCR1, we found that additional proline biosynthetic enzymes, such as ALDH18A1, were upregulated in HCC models and also regulated HCC cell proliferation. Clinical data demonstrated that PYCR1 expression was increased in HCC, correlated with tumor grade, and was an independent predictor of clinical outcome. CONCLUSION: Enhanced expression of proline biosynthetic enzymes promotes HCC cell proliferation. Inhibition of PYCR1 or ALDH18A1 may be a novel therapeutic strategy to target HCC. LAY SUMMARY: Even with the recently approved immunotherapies against liver cancer, currently available medications show limited clinical benefits or efficacy in the majority of patients. As such, it remains a top priority to discover new targets for effective liver cancer treatment. Here, we identify a critical role for the proline biosynthetic pathway in liver cancer development, and demonstrate that targeting key proteins in the pathway, namely PYCR1 and ALDH18A1, may be a novel therapeutic strategy for liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ding Z, Ericksen RE, Escande-Beillard N, et al. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J Hepatol. 2019. PMID: 31726117. doi:10.1016/j.jhep.2019.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。